NewLimit secures $40 million in venture funding from Dimension Capital, Founders Fund, Kleiner Perkins and other investors
NewLimit works across cell biology, genomics, machine learning, and cellular reprogramming to treat diseases and reverse aging
NewLimit has secured $40 million in Series A funding from Dimension, Founders Fund, and Kleiner Perkins with participation from Eric Schmidt, Elad Gil, Garry Tan, and Fred Ehrsam. These investors have built and funded generational companies across the biotechnology and software industries. We are excited to partner with all of them.
NewLimit was founded to cure aging. We are working toward this goal by uncovering sets of transcription factors that can epigenetically reprogram cells. Although our products are designed to treat aging itself, we also believe these products could treat or prevent many diseases associated with aging, including fibrosis, infectious disease, and neurodegenerative disease.
This new funding is in addition to the founders’ original $110 million commitment to the company. With the additional capital we plan to remain a small focused team where everyone contributes to the line work and everyone contributes to company building. There are no shortcuts.
Many investors talk about funding transformative companies but few are willing to take on the risk inherent in these kinds of projects. Even though aging is the dominant driver of human disease, aging biology has been underfunded and under-explored. We believe epigenetic reprogramming is a watershed moment for aging research and we hope to spur many more groups to participate in moving this field forward. We are grateful to our investors for their belief in our team and approach.
If you have skills in functional genomics, single cell assays, software development, machine learning, bioinformatics or research operations, please come invent the future with us at newlimit.com/careers.